COVID-19：AGC 生产 Pfizer-BioNTech 疫苗：质粒 DNA
AGC Biologics ‘海德堡：
6 月 8 日，AGC Biologics 受委托“制造质粒 DNA，这是辉瑞-BioNTech COVID-19 疫苗的原料”。
Pfizer-BioNTech COVID-19 疫苗：（日文名称：Kominati）
该社区是由美国辉瑞公司和德国BioNTech联合开发的疫苗。
它是一种所谓的“mRNA疫苗”。
日本批准的特别批准：
在日本，
2021年2月，作为日本首个疫苗
辉瑞 BioNTech COVID-19 疫苗被批准为特例。
截至6月7日，已完成超过1600万次接种。
2021 年，辉瑞 BioNTech 疫苗将交付 1.94 亿剂。
日本商业内幕
https://www.businessinsider.jp/post-236366
AGC Biologics’ Heidelberg Facility to Further Supply Plasmid DNA for COVID-19 Vaccine
AGC (Headquarters: Tokyo), a world-leading manufacturer of glass, chemicals, and high-tech materials,
has announced that its biopharmaceutical CDMO subsidiary, AGC Biologics (Headquarters: United States), has announced its partnership with BioNTech SE (Nasdaq BNTX)
to further supply Plasmid DNA (pDNA) starting material for the Pfizer-BioNTech COVID-19 vaccine, at AGC’s Heidelberg, Germany facility.
We are honored that
BioNTech has entrusted us to become part of their global supply network in an effort to make the vaccine available to as many people as possible around the world,” says AGC Biologics Chief Business Officer, Mark Womack.
We are very proud of our efforts
to provide our global customers with the essential materials needed to rapidly deliver vaccines in the fight against the COVID-19 pandemic.
AGC Biologics
will manufacture and supply BioNTech with pDNA starting material, an essential component of BioNTech’s mRNA-based vaccine manufacturing process.
AGC Biologics’ Heidelberg facility
has over 20 years of experience delivering a very wide range of microbial programs for our customers.
In addition,
the site is AGC’s Center of Excellence for Plasmid DNA (pDNA) production, as part of their end-to-end Cell and Gene Therapy offering.
The Pfizer-BioNTech COVID-19 Vaccine, which is based on BioNTech proprietary mRNA technology,
was developed by both BioNTech and Pfizer.
BioNTech is the Marketing Authorization Holder in the European Union,
and the holder of emergency use authorizations or equivalents
in the United States (jointly with Pfizer), United Kingdom,
Canada and other countries
in advance of a planned application for full marketing authorizations in these countries.
News ｜ AGC News ｜ AGC